Alumis (ALMS) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.79

Estimate

-$0.71

Surprise

-11.3%

Revenue (period 2026-06-30)

$1.7M

Score today

4.5/10

Revenue source: xbrl.

Alumis (ALMS) reported a wider loss than forecast — diluted EPS of -$0.79 against the -$0.71 estimate (a 11.3% shortfall).

• HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target — benzinga, 2026-08-14
• Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate — benzinga, 2026-08-13
• Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates — benzinga, 2026-08-11

TrendMatrix currently rates ALMS Sell at 4.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -11.3% surprise compares with a +12.8% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.10

Price target

$27.95

Stop

$10.32

Upside to target

+151.8%

Reward-to-risk

10.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.44B

P/E (fwd)

-3.9

52-week range

$3.76–$31.35

Off 52-week high

64.6%

RSI (14)

18

Volume vs avg

0.97×

Score today

4.5/10